PRIMECAP MANAGEMENT CO/CA/ - ZENTALIS PHARMACEUTICALS INC ownership

ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 109 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.92 and the average weighting 0.3%.

Quarter-by-quarter ownership
PRIMECAP MANAGEMENT CO/CA/ ownership history of ZENTALIS PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$20,737,025
-33.8%
1,033,750
-7.0%
0.02%
-30.8%
Q2 2023$31,345,542
+61.4%
1,111,150
-1.6%
0.03%
+52.9%
Q1 2023$19,417,424
-14.7%
1,128,920
-0.1%
0.02%
-19.0%
Q4 2022$22,761,624
-10.9%
1,130,170
-4.2%
0.02%
-16.0%
Q3 2022$25,552,000
-23.7%
1,179,700
-1.0%
0.02%
-16.7%
Q2 2022$33,495,000
-39.9%
1,192,000
-1.4%
0.03%
-28.6%
Q1 2022$55,764,000
-47.1%
1,208,590
-3.6%
0.04%
-42.5%
Q4 2021$105,381,000
+18.4%
1,253,640
-6.1%
0.07%
+15.9%
Q3 2021$89,006,000
+24.1%
1,335,620
-1.0%
0.06%
+31.2%
Q2 2021$71,746,000
+23.8%
1,348,610
+1.0%
0.05%
+20.0%
Q1 2021$57,944,000
-18.7%
1,335,430
-2.6%
0.04%
-24.5%
Q4 2020$71,246,000
+57.6%
1,371,690
-0.8%
0.05%
+43.2%
Q3 2020$45,202,000
+42.6%
1,382,750
+109.5%
0.04%
+37.0%
Q2 2020$31,691,000659,9500.03%
Other shareholders
ZENTALIS PHARMACEUTICALS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Paradigm Biocapital Advisors LP 300,434$25,254,0007.21%
TYBOURNE CAPITAL MANAGEMENT (HK) LTD 2,628,409$220,944,0006.56%
Avidity Partners Management LP 2,715,000$228,223,0004.84%
Matrix Capital Management Company, LP 4,349,279$365,600,0004.07%
Affinity Asset Advisors, LLC 117,500$9,877,0003.59%
Integral Health Asset Management, LLC 120,000$10,087,0002.79%
Ghost Tree Capital, LLC 80,000$6,725,0002.41%
Ikarian Capital, LLC 191,140$16,067,0002.39%
Tri Locum Partners LP 23,632$1,987,0000.78%
Eventide Asset Management 529,000$44,468,0000.57%
View complete list of ZENTALIS PHARMACEUTICALS INC shareholders